Austrian physicians conducting an additional Phase III clinicalstudy of Immunomedics Inc.'s colorectal cancer imaging agentsaid ImmuRAID-CEA "had a decisive influence on treatmentplanning in every third primary colorectal cancer patient" andwas superior to a CT-scan in the detection of early recurrences.

The Morris Plains, N.J., company (NASDAQ:IMMU) presentedthe paper to the American Society of Colorectal SurgeonsCongress in San Francisco.

The study, reported by Peter Lechner of the University of Graz,Austria, found that in a group of 32 patients with suspectedprimary colorectal cancer, Immunomedics' kit correctly foundthe primary cancers in 28 of 29 patients who had cancer atsurgery. In patients who were being followed for recurrence ormetastasis, use of the kit led to correct identification of 12 outof 12 patients with recurrent cancers, the company said.

There were no side effects, said company spokesman JosephSchepers.

Additional trials are being conducted primarily to accumulatedata on multiple dosages, Schepers said.

More than 150,000 new cases of colorectal cancer arediagnosed each year both in the U.S. and Europe, he said.

Immunomedics filed in April 1991 for FDA approval in the U.S.and in April of this year for European approval by theCommittee for Proprietary Medicinal Products.

(c) 1997 American Health Consultants. All rights reserved.